Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Immunotherapies
 More »

  • The Tumor Microenvironment as a Drug Target: Chasing Slippery...
    ... inhibit FAP activity at the molecular level; she and others are also "trying to kill off the cells that express FAP with antibody-conjugated toxin and cell-based immunotherapies." ...
    5-1-2013
  • FusionVax Snags Exclusive Rights to HPV Drug in Asia
    FusionVax is a private Taiwan-based biopharmaceutical company developing immunotherapies for the treatment of HPV-associated cancers. It is committed to in-licensing and developing ...
    4-22-2013
  • Novel Platform for Immunotherapies Created
    for the creation of a new industrial platform for the production of immunotherapeutics, including Transgene's therapeutic products. Novel Platform for Immunotherapies Created
    3-26-2013
  • Medicine: Getting Personal
    ... COO and vp of manufacturing at Argos Therapeutics, presented a case study summarizing the do's and don'ts of an automated approach for scale-up of personalized immunotherapies. ...
    3-15-2013
  • Zapping Pathological Proteins in Alzheimer's
    is the basis for active and passive immunotherapies against conformation-specific targets. ... AC Immune's immunotherapies trigger the body to make antibodies against these misfolded ...
    3-1-2013
  • Rise of Cell-Based Immunotherapy
    ... While the pendulum swinging in favor of immunotherapies is not restricted to cell-based ... pipeline with a view to revisit cell-based immunotherapies with a more favorable eye. ...
    3-1-2013
  • Troubled Dendreon Sells Off NJ Plant
    to University of Pennsylvania toward creation of a Center for Advanced Cellular Therapies, under a new R&D alliance designed to advance novel T-cell immunotherapies against cancer. ...
    12-20-2012
  • Sanofi Deal Could Net Selecta Up to $900M
    The accord also gives Sanofi an option to develop two additional candidate immunotherapies for allergies, each to a specific food or aeroallergen using SVP. The platform technology ...
    11-28-2012
  • Getting Cancer Immunotherapeutics Approved
    It's not just the FDA standing in the way. While biologically based therapeutic cancer vaccines and other cancer immunotherapies have great promise in treating certain cancers, ...
    11-13-2012
  • Cellular Therapy Wave Finally Cresting
    Cell-based immunotherapies such as cancer vaccines are not considered a part of cellular ... with the exception of cell-based immunotherapies or cell-delivered gene therapy, both ...
    11-1-2012
  • MedImmune Partnership Tests Anticancer Combinations in the Clinic
    evaluating combinations of cancer immunotherapies, including MedImmune's antibody ... evaluating combinations of cancer immunotherapies, including MedImmune's antibody ...
    10-9-2012
  • CARs Against Cancer
    on developing targeted chimeric antigen receptor (CAR) immunotherapies against cancer. ... on the development of adoptive T-cell immunotherapies through collaborative research. ...
    8-6-2012
  • JDRF, Novo Nordisk Ink Type 1 Diabetes Partnership as Firm Opens...
    JDRF and Novo Nordisk established a collaboration focused on the discovery and development of immunotherapies for the prevention and treatment of type 1 diabetes (T1D). The ...
    6-14-2012
  • Autologous Immunotherapy Updates at ASCO Further Define Antitumor...
    ... At the end of the day it's the clinical story that drives FDA approval, but understanding mechanism of action will help us design even more potent immunotherapies for cancer." Dr. ...
    6-1-2012
  • Advaxis Taps Karolinska Researcher to Test Immunotherapies Against...
    Advaxis inked a research collaboration to evaluate its immunotherapies against allergies ... Dr. van Hage will be using Advaxis immunotherapies to develop allergy treatments using the ...
    4-6-2012
  • More »

    Journal Articles

  • DNA/Amphiphilic Block Copolymer Nanospheres Reduce Asthmatic...
    Marie Langelot, Mathieu Mével, Benoit Chatin, David Lair, Antoine Magnan, Bruno Pitard, Fanny Beilvert, Adrien Tissot, Mathieu Mevel
    Human Gene Therapy and Part B: Methods
    reactivity against allergens. The most promising treatments for asthma are based on specific immunotherapies, but they lack efficiency and can induce deleterious side effects. ...
  • Characterization of Monoclonal Antibodies to Terminal and Internal...
    Marly I. Roche, Zhaohua Lu, Julia H. Hui, Jacqueline Sharon
    Hybridoma
    These findings demonstrate that non-overlapping epitopes can be targeted by antibodies to Ft OAg, which may inform the design of vaccines and immunotherapies against tularemia.
  • Characterization of a Novel Human Anti-HIV-1 gp41 IgM Monoclonal...
    Chuanhai Cao, Yun Bai, Mary Jolene Holloway, Rebecca L. Edgeworth, Eugene A. Jackson, Joseph Cotropia, Kenneth E. Ugen
    DNA and Cell Biology
    less hypervariability than the gp120 surface envelope HIV glycoprotein, which makes it particularly a better candidate for the development of passive and active immunotherapies. ...
  • Vaccine of Engineered Tumor Cells Secreting Stromal Cell-Derived...
    Meiqing Shi, Siguo Hao, Liping Su, Xueshu Zhang, Jinying Yuan, Xuling Guo, Changyu Zheng, Jim Xiang
    Cancer Biotherapy and Radiopharmaceuticals
    natural adjuvant activities that may augment antitumor responses through their effects on T-cells and thereby could be important in gene transfer immunotherapies for some cancers.

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll